Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
Clinical trial NCT05623410 · UNKNOWN
Trial details
- NCT number
- NCT05623410
- Sponsor
- ATGC Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-11
- Primary completion
- 2023-02-10
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.